Neurontin®
Gabapentin
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$600+ (brand Neurontin)
With Insurance
$5–20
How It Works
Despite its name, gabapentin does not directly activate GABA receptors. Instead, it attaches to a subunit of voltage-gated calcium channels in neurons, reducing calcium entry and therefore reducing the release of excitatory neurotransmitters — dampening overactive pain signaling.
Why the side effects happen
Calcium channel inhibition throughout the brain (not just pain pathways) explains the widespread sedation, dizziness, and cognitive impairment. The dose-response curve for side effects is linear while the pain-relief curve plateaus — meaning higher doses produce proportionally more side effects without proportionally more benefit. Gabapentin's unpredictable gut absorption (non-linear pharmacokinetics) means doubling the dose does not double the blood level.
When Will I Feel It?
Pain relief typically begins within 1 week. Full effect takes 4–8 weeks at therapeutic dose. If no improvement by 8 weeks, gabapentin is unlikely to be effective for that specific condition.
Initial reduction in nerve pain or seizure frequency. Sedation and dizziness are typically most intense in this phase.
Dose titration phase — dose is gradually increased to minimize side effects. Pain relief building.
Maximum therapeutic effect at target dose. The NNT (number needed to treat) for postherpetic neuralgia is approximately 4–5 — meaning 4–5 patients need to take it for 1 to experience meaningful relief.
Reassess whether benefit still outweighs side effects. Tolerance to pain relief can develop; if dose is repeatedly being escalated, reassess diagnosis and alternatives.
Adherence Note
Only 30–40% of patients taking gabapentin for neuropathic pain achieve meaningful (≥50%) pain reduction. If you're at 8 weeks at therapeutic dose with no meaningful improvement, gabapentin is unlikely to be the right drug for your condition.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Dizziness / vertigo
28%Most common reason for stopping. Rise slowly; avoid ladders or heights. Usually improves after 1–2 weeks.
Somnolence / excessive sedation
21%Do not drive or operate machinery until you know your response. May not improve with time at higher doses.
Ataxia (loss of coordination)
13%Fall hazard, especially in elderly. Consider dose reduction if persistent.
Fatigue
11%Often improves; take larger portion of dose at night.
Weight gain
3–10%Average 2–5 lbs in first year. Mechanism: increased appetite, decreased activity due to sedation.
Peripheral edema (ankle swelling)
8%Common at higher doses. Elevate legs; reduce dose if significant. May indicate need to reassess.
Cognitive impairment / "brain fog"
2–3%Memory and processing speed affected. At higher doses, can be significant. Report to doctor.
Serious Adverse Effects
- • Respiratory depression — especially when combined with opioids, benzodiazepines, or alcohol; increasingly implicated in overdose deaths
- • Physical dependence — gabapentin withdrawal syndrome includes anxiety, insomnia, nausea, sweating, and seizures; risk highest with abrupt cessation after high-dose chronic use
- • Suicidality — FDA black box warning for all anticonvulsants; increased risk of suicidal thoughts and behavior
- • Mood changes / paradoxical agitation — especially in children and adolescents
- • Drug abuse potential — significant street value; used recreationally for euphoria especially in combination with opioids
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Respiratory depression — especially when combined with opioids, benzodiazepines, or alcohol; increasingly implicated in overdose deaths
- Physical dependence — gabapentin withdrawal syndrome includes anxiety, insomnia, nausea, sweating, and seizures; risk highest with abrupt cessation after high-dose chronic use
- Suicidality — FDA black box warning for all anticonvulsants; increased risk of suicidal thoughts and behavior
- Mood changes / paradoxical agitation — especially in children and adolescents
- Seizures — emergency; call 911
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Animal studies show developmental toxicity. Human data limited; associated with small-for-gestational-age infants. Use only if clearly indicated and benefit outweighs risk.
Excreted in breast milk. Monitor infant for sedation and feeding difficulties. Lower-dose exposure is generally considered acceptable for seizure management.
Gabapentin is frequently used off-label for menopausal hot flashes, particularly for women who cannot or choose not to use hormone therapy. It reduces hot flash frequency and severity. However, it doesn't address other menopause symptoms and carries dependence, cognitive fog, and sedation risks. Discuss the full range of menopause management options — including hormone therapy — with your doctor.
FDA approved for partial seizures in children 3+. Off-label use for behavior, ADHD, anxiety, and pain in children is not supported by adequate evidence. Black box warning for suicidality applies.
Dizziness, ataxia, and sedation cause significant fall risk. Start at lowest dose (100mg) and titrate slowly. Renal function declines with age — dose must be adjusted for creatinine clearance.
Gabapentin is renally cleared. Dose must be substantially reduced based on creatinine clearance (eGFR). Accumulation in renal impairment can cause severe toxicity.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Neuropathic & Chronic Pain Without Gabapentinoids
The evidence for gabapentin in many chronic pain conditions is weak — lifestyle and targeted interventions often provide comparable relief without dependency or sedation
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Alpha lipoic acid (600mg/day)
ModerateFor diabetic peripheral neuropathy specifically
Multiple RCTs show ALA reduces diabetic neuropathy pain and improves nerve conduction; comparable to gabapentin with superior safety profile
Physical therapy (graded motor imagery)
ModerateSupervised exercise + GMI for central sensitization pain
Graded motor imagery reduces neuropathic and chronic pain by retraining the brain's pain processing; evidence strongest for CRPS
Low-carbohydrate diet
ModerateFor diabetic neuropathy — address the root cause
Reducing blood glucose directly reduces glycation damage to peripheral nerves; HbA1c normalization slows neuropathy progression
Capsaicin 8% patch (Qutenza)
StrongPrescription topical; applies to pain area
FDA-approved for postherpetic neuralgia and diabetic neuropathy; depletes substance P locally — no systemic side effects
TENS (Transcutaneous Electrical Nerve Stimulation)
ModerateAt-home device; applied to pain area
Modulates pain signaling via gate control mechanism; evidence for chronic neuropathic pain and fibromyalgia
Key Studies
How It Compares
Gabapentin and pregabalin (Lyrica) have the same mechanism. Pregabalin has more predictable absorption (linear pharmacokinetics), is FDA-approved for more pain conditions, and is Schedule V. For diabetic neuropathy, duloxetine (SNRI) is guideline-preferred over gabapentinoids.
Strengths
- Cheap ($20–60/month generic)
- Not federally scheduled (in most states)
- Multiple evidence-based indications (epilepsy, PHN)
- Can be used in opioid-sparing protocols
Weaknesses
- Non-linear absorption (dose escalation unpredictable)
- 83% of use is off-label
- Opioid overdose risk (respiratory depression potentiation)
- State-level scheduling due to abuse epidemic
- Criminal off-label marketing history
Clinically Preferred Alternatives
Global Prescribing & Pricing
United States
$20–60/mo
83% of prescriptions are off-label; massive prescribing for pain conditions with limited evidence
No federal scheduling despite abuse potential. Several states (KY, TN, MI, WV, VA) independently added gabapentin to Schedule V due to epidemic abuse rates.
Usually covered
United Kingdom
~$5–15/mo
Became Class C controlled substance in 2019 due to abuse epidemic
NHS England and the MHRA added gabapentin (and pregabalin) to Schedule 3 Class C controlled substances in April 2019, following a marked increase in abuse-related deaths — particularly in combination with opioids.
NHS covered — controlled prescription required
Germany
~$10–20/mo
More conservative prescribing for non-epilepsy indications
German guidelines restrict gabapentinoids to well-documented indications; off-label use requires documented justification and specialist involvement.
GKV covered for approved indications
Australia
~$10–25/mo
PBS restricts to approved indications; limited off-label subsidization
TGA has issued warnings about gabapentin abuse; PBS coverage is restricted to approved indications with documented diagnosis.
PBS — restricted to approved indications
The UK's 2019 decision to schedule gabapentin as a controlled substance was driven by data showing it was a major contributor to opioid-related deaths. The US, where abuse rates are similarly high, has not made this change at the federal level — leaving states to act independently.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
Parke-Davis (now part of Pfizer) was the first pharmaceutical company ever convicted of criminal off-label drug marketing in the US. In 2004, Pfizer paid $430 million in criminal fines and civil penalties for promoting Neurontin for pain, bipolar disorder, ADHD, migraines, and drug withdrawal — none of which were FDA approved. Internal documents from the case revealed deliberate "publication planning" to manufacture scientific evidence through paid ghost-writing, suppression of negative studies, and scripting of "independent" talks by paid physicians. By 2004, 83% of Neurontin prescriptions were off-label.
Declared Conflicts of Interest
The DOJ case revealed that Parke-Davis paid physicians up to $3,000/day to give promotional talks disguised as education. Internal emails showed explicit instructions to suppress negative study results and only publish positive outcomes. The Cochrane reviews on gabapentin for pain show industry-funded trials consistently report more positive results than independent studies — by a substantial margin.
Key Efficacy Results
FDA approved for epilepsy and postherpetic neuralgia only. Evidence for other pain uses (back pain, fibromyalgia, general neuropathy) is weak to moderate. The 2019 Cochrane review on gabapentin for chronic neuropathic pain found it helps only 30–40% of patients, with many experiencing significant side effects.
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Gabapentin. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Gabapentin in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| Parke-Davis/Pfizer $430M Criminal Conviction | DOJ-2004 | |
| Gabapentin Off-Label Prescribing Analysis | PMID:25879938 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Gabapentin acts on GABA and calcium channels; abrupt discontinuation after chronic use causes a withdrawal syndrome that includes severe anxiety, insomnia, nausea, sweating, and — in high-dose users — seizures. Many patients and prescribers are unaware of gabapentin dependence because it is "not a controlled substance" federally. This does not mean it is free of dependence risk.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Published protocols describe reducing by no more than 10% of the dose every 1–2 weeks
- ·Research supports tapering over 3–6 months for high-dose users (>2400mg/day)
- ·Research documents that abrupt discontinuation in patients using gabapentin for seizure control carries risk of breakthrough seizures
- ·Research recommends monitoring for anxiety and insomnia — these are documented early signs of withdrawal
- ·Research supports having an alternative pain management plan in place for the underlying condition during the stopping process
Warning Symptoms — Contact Your Doctor If You Experience:
- Seizures — emergency; call 911
- Extreme agitation or confusion
- Severe sweating and tremors
- Uncontrollable anxiety or panic
- Any symptoms resembling alcohol or benzodiazepine withdrawal
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.Is my use of gabapentin for an FDA-approved indication, or is this off-label? What is the evidence strength for my specific condition?
- 2.Given gabapentin is implicated in overdose deaths with opioids, can we review all my medications for this combination?
- 3.I live in a state where gabapentin is a controlled substance — does this change how you monitor my use?
- 4.What is the plan if this medication stops working or I want to stop — what does the taper look like?
- 5.Have non-drug alternatives (physical therapy, alpha lipoic acid, TENS) been considered for my condition?
Lab Tests to Request
- Renal function (eGFR) — dose must match kidney function
- PHQ-9 (depression screen — suicidality black box)
- Abuse/misuse screen if any risk factors
- Annual review of whether off-label use still has ongoing benefit
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Neurontin®
- What is Neurontin® used for?
- Neurontin® (Gabapentin) is a Anticonvulsant / Gabapentinoid manufactured by Pfizer (originally Parke-Davis) / Generic. FDA-approved indications include: Partial seizures (with and without secondary generalization); Postherpetic neuralgia (shingles pain); Off-label (unproven): fibromyalgia, general neuropathic pain, back pain, restless legs, alcohol withdrawal, anxiety, bipolar disorder.
- What are the common side effects of Neurontin®?
- Common side effects of Neurontin® include: Dizziness / vertigo (28%); Somnolence / excessive sedation (21%); Ataxia (loss of coordination) (13%); Fatigue (11%); Weight gain (3–10%).
- How much does Neurontin® cost?
- Neurontin® list price is approximately $600+ (brand Neurontin). With insurance it typically costs $5–20; without insurance approximately $20–60.
- Who funded the clinical trials for Neurontin®?
- Parke-Davis (now part of Pfizer) was the first pharmaceutical company ever convicted of criminal off-label drug marketing in the US. In 2004, Pfizer paid $430 million in criminal fines and civil penalties for promoting Neurontin for pain, bipolar disorder, ADHD, migraines, and drug withdrawal — none of which were FDA approved. Internal documents from the case revealed deliberate "publication planning" to manufacture scientific evidence through paid ghost-writing, suppression of negative studies, and scripting of "independent" talks by paid physicians. By 2004, 83% of Neurontin prescriptions were off-label.
- How strong is the clinical evidence for Neurontin®?
- Key studies: Parke-Davis off-label marketing case (Franklin v. Parke-Davis), multiple industry-funded pain trials, 2004 DOJ settlement. FDA approved for epilepsy and postherpetic neuralgia only. Evidence for other pain uses (back pain, fibromyalgia, general neuropathy) is weak to moderate. The 2019 Cochrane review on gabapentin for chronic neuropathic pain found it helps only 30–40% of patients, with many experiencing significant side effects. Potential conflicts of interest: The DOJ case revealed that Parke-Davis paid physicians up to $3,000/day to give promotional talks disguised as education. Internal emails showed explicit instructions to suppress negative study result.
- Are there non-drug alternatives to Neurontin®?
- The evidence for gabapentin in many chronic pain conditions is weak — lifestyle and targeted interventions often provide comparable relief without dependency or sedation See the Alternatives tab for full details.
Get notified when we update Neurontin®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.